| Magalang, Ulysses |
| Recruiting | N/A | 500 | US, RoW | Positive Airway Pressure | University of Pennsylvania, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | Obstructive Sleep Apnea | 11/27 | 04/28 | | |
| Active, not recruiting | N/A | 900 | US | aerSleep II | Sommetrics, Inc. | Sleep Apnea, Obstructive, Apnea, Sleep | 12/25 | 12/25 | | |
NCT01857427: A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities |
|
|
| Active, not recruiting | N/A | 5000 | US | | Ulysses Magalang MD | Obstructive Sleep Apnea | 12/25 | 12/25 | | |
NCT05742360: Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype |
|
|
| Recruiting | N/A | 227 | US | CPAP therapy | Ohio State University, University of Pennsylvania | Obstructive Sleep Apnea | 03/27 | 03/28 | | |
NCT04712656: Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea |
|
|
| Recruiting | N/A | 1739 | US | CPAP therapy | Ohio State University, University of Pennsylvania, Chang Gung Memorial Hospital, University of Sydney, The University of Western Australia, Peking University, Ruijin Hospital, National University of Singapore, University of Iceland, Geisinger Health, Charite University, Berlin, Germany | Sleep Apnea, Obstructive | 03/31 | 03/32 | | |
| Brothers, Trish |
NCT03727880: Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Pembrolizumab, MK-3475, Keytruda, Defactinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Verastem, Inc. | Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 12/24 | 12/24 | | |
NCT03638141: CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab |
|
|
| Completed | 2 | 21 | US | Durvalumab, MEDI4736, Tremelimumab (Cohort A dose), CP-675,206, Tremelimumab (Cohort B dose) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma | 08/24 | 08/24 | | |
NCT03642067: Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer |
|
|
| Completed | 2 | 59 | US | Nivolumab, OPDIVO, BMS-936558, anti-PD-1, Relatlimab, BMS-986016, anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma | 02/24 | 09/24 | | |
NCT04209686: Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 36 | US | Paclitaxel, Taxol, Olaparib, Lynparza, Pembrolizumab, MK-3475; Keytruda | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Advanced Gastric Adenocarcinoma | 04/28 | 04/28 | | |
NCT03607890: Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor |
|
|
| Recruiting | 2 | 42 | US | Nivolumab, anti-PD-1, OPDIVO, Relatlimab, BMS-986016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI) | Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors | 10/25 | 10/25 | | |
CA209-8DP, NCT03521830: Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma |
|
|
| Recruiting | 2 | 57 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Relatlimab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Basal Cell Carcinoma | 03/26 | 03/27 | | |
NCT04116073: INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer |
|
|
| Completed | 2 | 25 | US | INCMGA00012 (PD-1 antibody), MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic | 08/24 | 12/24 | | |
NCT05014776: Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 17 | US | Tadalafil, CIALIS®, Pembrolizumab, KEYTRUDA®, Ipilimumab, YERVOY®, CRS-207 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Lustgarten Foundation, National Cancer Institute (NCI) | Pancreatic Cancer | 04/24 | 04/25 | | |
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
|
|
| Recruiting | 2 | 38 | US | Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC | Metastatic Pancreatic Cancer | 12/25 | 12/29 | | |
NCT05604560: A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer |
|
|
| Recruiting | 2 | 25 | US | Tislelizumab, BGB-A317, SX-682 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, BeiGene, Syntrix Biosystems, Inc. | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT03767582: Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. |
|
|
| Completed | 1/2 | 46 | US | Stereotactic Body Radiation (SBRT), Nivolumab, OPDIVO, CCR2/CCR5 dual antagonist, BMS-813160, GVAX, PANC 10.05 pcDNA-1/GM-Neo vaccine, PANC 6.03 pcDNA-1/GM-Neo vaccine | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma | 09/24 | 09/24 | | |
NCT04799431: Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer |
|
|
| Withdrawn | 1 | 12 | NA | Neoantigen Vaccine with Poly-ICLC adjuvant, Hiltonol® (Poly-ICLC), Retifanlimab, INCMGA00012; MGA012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation, National Cancer Institute (NCI) | Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic | 05/23 | 05/23 | | |
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer |
|
|
| Recruiting | 1 | 30 | US | KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY® | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH) | Colorectal Cancer, Pancreatic Cancer | 08/25 | 08/25 | | |
NCT04658147: Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 1 | 20 | US | Nivolumab, OPDIVO™, BMS 936558, MDX1106, ONO-4538, Relatlimab, BMS-986016, BMS-986016-01, Anti-LAG-3 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb | Hepatocellular Carcinoma | 06/25 | 06/26 | | |
NCT05013216: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer |
|
|
| Recruiting | 1 | 37 | US | Cohort A: Patients at high risk of developing pancreatic cancer., Hiltonol® (Poly-ICLC), Cohort B: Patients must have evidence of a pancreatic cystic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Stand Up To Cancer | High Risk Cancer, Pancreatic Cancer | 05/26 | 05/26 | | |
